// App-Quantinova.ai

TPS4146 : PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy pexaavec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.

Researchers

Presenter

  • Ghassan K. Abou-Alfa

Principal Investigators

  • Peter R. Galle

  • Yee Chao

  • Karen T. Brown

  • Jeong Heo

  • Mitesh J. Borad

  • Angelo Luca

  • Adina Pelusio

  • Delphine Agathon

  • Monika Lusky

  • Caroline Breitbach

  • James Burke

  • Shukui Qin

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University Medical Center Mainz, Mainz, Germany

  • Taipei Veterans General Hospital, Taipei City, Taiwan

  • Mayo Clinic, Scottsdale, AZ

  • IRCCS-ISMETT University of Pittsburgh Medical Center (UPMC), Palermo, Italy

  • Sillajen, Inc, San Francisco, CA

  • Transgene SA, Illkirch-Graffenstaden, France

  • Medical Oncology Department, Nanjing Bayi Hospital, Nanjing, China

Locations

  • Taiwan

  • China

  • Italy

  • Germany

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Sorafenib

  • TG6006

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02562755

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved